• SIRT1/2 Inhibitor IV (cambinol): Mechanism, Evidence & Use

  2026-07-07

  SIRT1/2 Inhibitor IV (cambinol) is a potent, cell-permeable small molecule that specifically inhibits SIRT1 and SIRT2 deacetylases, impacting cellular metabolism, tumor growth, and epigenetic signaling. Recent studies highlight its value in dissecting SIRT1-driven lactylation and astrocyte polarization after CNS injury. This dossier synthesizes mechanistic, experimental, and workflow-critical facts for advanced research.

• Cy7 NHS Ester: Near-Infrared Dye for Protein Labeling Workfl

  2026-07-07

  Cy7 NHS ester (SKU A8109) is a sulfonated, hydrophilic near-infrared dye designed to label amino groups on proteins and peptides for non-destructive, high-sensitivity imaging in vitro and in vivo. It addresses challenges in labeling delicate biomolecules by minimizing denaturation and fluorescence quenching. This reagent is not recommended for applications requiring long-term solution stability or for targets lacking primary amines.

• Chlorin e6 (Ce6) Photosensitizer: Evidence and Protocols in

  2026-07-06

  Chlorin e6 (Ce6) is a validated second-generation photosensitizer with reproducible efficacy in photodynamic therapy (PDT), enabling potent reactive oxygen species (ROS) generation and cytotoxicity. Recent preclinical and clinical studies demonstrate its anticancer and antibacterial activity, with detailed dosing and irradiation parameters now available for translational workflows.

• Bacitracin (B1670): Technical Guidance for Antibacterial Res

  2026-07-06

  Bacitracin is a peptide antibiotic formulated for laboratory research focused on disrupting bacterial cell wall and peptidoglycan synthesis in both gram-positive and gram-negative bacteria. It is not intended for diagnostic or clinical use and should be applied strictly within controlled experimental workflows.

• FPH1 (BRD-6125) Unlocks Hepatocyte Proliferation Assays

  2026-07-05

  FPH1 (BRD-6125) enables robust, donor-independent expansion of functional human hepatocytes, streamlining workflows for drug discovery and regenerative medicine. Its protocol-driven optimization elevates albumin and CYP3A4 outputs, while new optogenetic gene control strategies from the latest literature point to next-gen assay integration.

• SU6656 Src Tyrosine Kinases Inhibitor: Optimizing Platelet E

  2026-07-04

  Unlock new efficiency in hiPSC-derived platelet production and radiotherapy sensitization with SU6656 Src tyrosine kinases inhibitor. This guide delivers actionable protocol enhancements, troubleshooting strategies, and insights from the latest reference studies, accelerating translational hematology and oncology workflows.

• 3-(2-Methoxy-5-pyridyl)-Ala Modifications in GnRH Antagonist

  2026-07-03

  This study explores the structural modification of Degarelix analogs by substituting position 3 with 3-(2-methoxy-5-pyridyl)-alanine, analyzing effects on GnRH receptor antagonism and in vivo duration. Results highlight stereospecific impacts on potency and underscore challenges in optimizing antagonist duration for prostate cancer research.

• Bile Acid Metabolism Subtypes Mark Immune Dysfunction in CRC

  2026-07-03

  Feng et al. (2026) classified colorectal cancer into molecular subtypes based on bile acid metabolism, revealing that low bile acid activity correlates with poor prognosis and pronounced immune dysfunction. The study identifies CLCA1, UGT2A3, and ZG16 as key genes shaping the tumor immune microenvironment and provides potential biomarkers for stratification and therapeutic targeting in CRC.

• Coronavirus Macrodomain Counters PARP-Mediated Antiviral Imm

  2026-07-02

  This study demonstrates that the coronavirus macrodomain is essential for evading host PARP-mediated antiviral responses, particularly through counteracting PARP12 and PARP14 activities. These findings clarify the interplay between viral macrodomains and host poly (ADP-ribose) polymerases, offering mechanistic insight for antiviral research and the modulation of innate immunity.

• Ranolazine: Anti-Ischemic Agent for Cardiac and Hepatic Assa

  2026-07-02

  Ranolazine's dual action as an anti-ischemic agent unlocks advanced metabolic and electrophysiological assays in both cardiac and hepatic models. This article details optimized protocols, experimental troubleshooting, and the translation of new mechanistic findings into practical workflows, setting a new standard for researchers seeking metabolic precision.

• Danazol in Endocrine Modeling: Mechanistic Insights and Prec

  2026-07-01

  Explore how Danazol serves as a cornerstone tool in modeling endocrine disorders through its nuanced inhibition of steroidogenesis and luteinizing hormone suppression. This article goes beyond protocols, delving into mechanistic depth and recent innovations for advanced endocrine research.

• Z-DEVD-FMK: Caspase-3 Inhibitor for Apoptosis and Neuroprote

  2026-07-01

  Z-DEVD-FMK is a cell-permeable, irreversible caspase-3 inhibitor with additional activity against caspase-6, -7, -8, and -10 as well as calpain. This compound enables precise modulation of apoptosis and has demonstrated neuroprotective effects in models of brain injury. Its robust inhibition profile makes it a critical tool for dissecting caspase signaling pathways in both oncology and neuroscience.

• D-Luciferin: Precision Firefly Luciferase Substrate for Biol

  2026-06-30

  D-Luciferin, a high-affinity firefly luciferase substrate, transforms bioluminescence imaging by enabling sensitive, non-invasive quantification of tumor burden, gene expression, and cell metabolism in live models. This article explores advanced workflow optimizations, troubleshooting strategies, and practical insights drawn from both foundational research and recent breakthroughs in immuno-oncology.

• Degarelix Acetate in Prostate Cancer: Rapid Androgen Depriva

  2026-06-30

  Degarelix acetate offers a clinically significant advance in the medical management of advanced prostate cancer by providing rapid, sustained androgen deprivation without the testosterone surge seen in traditional GnRH agonist therapy. This article reviews the methodological rigor and translational findings from the pivotal study, placing the innovation in context for researchers examining endocrine and epigenetic intervention strategies.

• Polyethylenimine Linear (PEI), MW 40,000: Reliable DNA Trans

  2026-06-29

  This article explores real-world challenges in cell-based assays, demonstrating how Polyethylenimine Linear (PEI), MW 40,000 (SKU K1029) delivers reproducible, high-efficiency transfection in demanding in vitro workflows. Evidence-based Q&As guide researchers through protocol optimization, data interpretation, and vendor selection, highlighting the scientific advantages of this trusted reagent.

450 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page